RPRoland W. Pfaeffle

Roland W. Pfaeffle

*This is an algorithmically generated author record based on publicly available information.

Roland W. Pfaeffle has a total of 28 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Kleinwuchs

    by R. Pfäffle, W. Kiess, R. Gausche, J. Kratzsch


  • Population-based cohort study: PROP1 gene mutations are the most prevalent cause of congenital multiple pituitary hormone deficiency in Lithuania

    by Ruta Navardauskaite, Petra Dusatkova, Barbora Obermannova, Roland W Pfaeffle, Werner F Blum, Dalia Adukauskiene, Natalija Smetanina, Ondrej Cinek, Rasa Verkauskiene, Jan Lebl

    Introduction: Congenital multiple pituitary hormone deficiency (MPHD) may result from defects of transcription factors that govern the early pituitary development. The most prevalent are two mutation of PROP1 gene: the c.296delGA and c.150delA. Methods: Seventy-five Lithuanian MPHD patients were tested for PROP1 defects. Perinatal and postnatal data were obtained from medical records. Hormonal investigations, pituitary imaging and GH therapy were performed at a single centre in Kaunas. The PROP1 gene was investigated by Sanger sequencing. Ancestral origin of mutation was assessed by genotyping of 22 single nucleotide polymorphisms flanking the PROP1 gene, and their haplotype analysis. Results: Fifty-two subjects (69.3%; 28 males; including ten sibling pairs and two sibling triples) from 38 families were found to carry a biallelic PROP1 gene mutation. Fifty of these were homozygous 296delGA and two were compound heterozygotes 296delGA/R71H and 296delGA/150delA. We found the highest rate of PROP1 mutations among MPHD patients from populations studied so far (17.5 per million). Patients’ birth lengths/weights were normal. Height declined to S.D. −1.56, −2.34, −3.43, −3.52, and −3.70 (medians) at years 1–5. Deficiencies of GH, TSH, ACTH, and FSH/LH were diagnosed in 50/52, 52/52, 21/52, and 25/52 subjects at median age 5.5; 5.6; 13.1, and 15.0 years respectively. Pituitary height ranged from 16.6 (+20.2 S.D.) to 1.4 mm (−15.5 S.D.) and declined with age (r2=0.27, P=0.001). GH therapy increased growth rates to 12.2; 9.1; 6.9; 6.8; 6.7; 5.6, and 5.7 cm/year (medians). The mutation carriers were found to share a common ancestor with the c.296delGA mutation having arisen about 112 generations ago (P≤3×10−4). Conclusions: The population-based cohort of patients with PROP1 gene mutation is the largest described so far. High prevalence of PROP1 defects in Lithuania is due to a founder effect of c.296delGA mutation.

  • Endokrine Ursachen eines intrauterinen Kleinwuchses

    by W. Kiess, J. Klammt, R. Pfäffle

    Zusammenfassung: Endokrine Ursachen eines intrauterinen Klein-wuchses galten bislang als sehr seltene monogene Krankheiten, klinisch von geringer Relevanz. Hierbei wurden bislang genetische Defekte des IGF-1-Gens und des IGF-1-Rezeptor (IGF1R)-Gens identifiziert. Während IGF-1-Genmutationen durch eine deutliche intrauterine und postnatale Wachstumsretardie-rung in Kombination mit einer psychomotorischen Retardierung und einer Innenohrschwerhörigkeit charakterisiert sind und homozygot vererbt werden, ist bei Patienten mit einer IGF1R-Mutation bis auf wenige Ausnahmen der Phänotyp auf eine Haploinsuffizienz für den Rezeptor zurückzuführen. Die steigende Anzahl nachgewiesener Mutationen in diesem Rezeptor verdeutlicht die Variabilität in der Ausprägung dieses Phänotyps und lässt vermuten, dass bei ca. 15 % aller Patienten mit einem intrauterinen Kleinwuchs, die IGFI-Serumspiegel im oberen Normbereich aufweisen, eine IGF1R-Mutation als Ursache der Wachstumsstörung nachweisbar ist. Eine differenzierte Untersuchung und langfristige klinische Verlaufsbeobachtung sind erforderlich, um die medizinische Versorgung dieser Patienten in Zukunft zu optimieren.

    • 1 January 2009
      • p. 283-90

    LHX3 and LHX4 transcription factors in pituitary development and disease.

    by Stephanie C Colvin, Rachel D Mullen, Roland W Pfaeffle, Simon J Rhodes

    The LHX3 and LHX4 LIM-homeodomain proteins are regulatory transcription factors that play overlapping but distinct functions during the establishment of the specialized cells of the mammalian pituitary gland and the nervous system. Recent studies have identified a variety of mutations in the LHX3 and LHX4 genes in patients with combined pituitary hormone deficiency diseases. These patients have complex and variable syndromes involving short stature, metabolic disorders, reproductive system deficits, and nervous system developmental abnormalities. The short stature secondary to growth hormone deficiency is a key feature of the disorders associated with these gene mutations and responds well to supplementation with recombinant growth hormone. Overall, the frequency of mutations in the LHX3 and LHX4 genes in patients with combined pituitary hormone deficiency is low. Mutations in other regulatory genes such as HESX1, PROP1, PIT1 / POU1F1, and GLI2 have been shown to be additional causes of pituitary hormone deficiency, but overall, the etiology of many cases of hypopituitarism is not understood. Further investigation is therefore required to identify other genes, both primary regulatory genes and those with modifier functions, which contribute to pituitary development and function.


  • Open Access

    Four Novel Mutations of the LHX3 Gene Cause Combined Pituitary Hormone Deficiencies with or without Limited Neck Rotation

    by Roland W. Pfaeffle, Jesse J. Savage, Chad S. Hunter, Christina Palme, Martina Ahlmann, Prasanna Kumar, Jaele Bellone, Eckhard Schoenau, Eckhard Korsch, JürGen H. BrämSwig, et al.

    Context: The Lhx3 LIM-homeodomain transcription factor gene is required for development of the pituitary and motoneurons in mice. Human LHX3 gene mutations have been reported in five subjects with a phenotype consisting of GH, prolactin, TSH, LH, and FSH deficiency; abnormal pituitary morphology; and limited neck rotation. Objective: The objective of the study was to determine the frequency and nature of LHX3 mutations in patients with isolated GH deficiency or combined pituitary hormone deficiency (CPHD) and characterize the molecular consequences of mutations. Design: The LHX3 sequence was determined. The biochemical properties of aberrant LHX3 proteins resulting from observed mutations were characterized using reporter gene and DNA binding experiments. Patients: The study included 366 patients with isolated GH deficiency or CPHD. Results: In seven patients with CPHD from four consanguineous pedigrees, four novel, recessive mutations were identified: a deletion of the entire gene (del/del), mutations causing truncated proteins (E173ter, W224ter), and a mutation causing a substitution in the homeodomain (A210V). The mutations were associated with diminished DNA binding and pituitary gene activation, consistent with observed hormone deficiencies. Whereas subjects with del/del, E173ter, and A210V mutations had limited neck rotation, patients with the W224ter mutation did not. Conclusions:LHX3 mutations are a rare cause of CPHD involving deficiencies for GH, prolactin, TSH, and LH/FSH in all patients. Whereas most patients have a severe hormone deficiency manifesting after birth, milder forms can be observed, and limited neck rotation is not a universal feature of patients with LHX3 mutations. This study extends the known molecular defects and range of phenotypes found in LHX3-associated diseases.